Pharmacological strategies in the prevention of relapse after electroconvulsive therapy

Journal of ECT

Volumn 29, Issue 1, 2013, Pages 3-12

  Prudic, Joan ^a   Haskett, Roger F ^b   McCall, W Vaughn ^c   Isenberg, Keith ^d   Cooper, Thomas ^a   Rosenquist, Peter B ^c   Mulsant, Benoit H ^b,e   Sackeim, Harold A ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

electroconvulsive therapy; lithium; nortriptyline; relapse prevention; venlafaxine

Indexed keywords

LITHIUM; NORTRIPTYLINE; PLACEBO; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FALLING; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MENTAL PATIENT; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; RISK REDUCTION; SEIZURE; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; EDUCATIONAL STATUS; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LITHIUM CARBONATE; MALE; MIDDLE AGED; NORTRIPTYLINE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84874655096     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e31826ea8c4     Document Type: Article

References (37)

1. Sackeim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10:96-104.
2. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839-846.
3. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425-434.
4. Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimulation. 2008;1:71-83.
5. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299-1307.
6. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63:1337-1344.
7. Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand. 1996;94:241-251.
8. Sackeim HA. Continuation therapy following ECT: directions for future research. Psychopharmacol Bull. 1994;30:501-521.
9. Prudic J, Olfson M, Sackeim HA. Electro-convulsive therapy practices in the community. Psychol Med. 2001;31:929-934.
10. Sackeim HA, Dillingham EM, Prudic J, et al. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry. 2009;66:729-737.
11. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axis I DSM-IV DisordersVPatient Edition (with Psychotic Screen) (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
13. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
14. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10-17.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, U.S. Government Printing Office, U.S. Department of Health, Education, and Welfare Publication, No. 76-338; 1976.
16. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual.2nd ed. San Antonio, TX: Psychological Corporation; 1996.
17. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
18. Kalbfleisch JD, Prentice RL. Survival Models and Data Analysis. New York, NY: John Wiley; 1980.
19. Peto R, Peto J. Asymptomatically efficient rank invariant procedure. J R Stat Soc Ser A. 1972;135:185-207.
20. Weiner RD, Whanger AD, Erwin CW, et al. Prolonged confusional state and EEG seizure activity following concurrent ECT and lithium use. Am J Psychiatry. 1980;137:1452-1453.
21. American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging. 2nd ed. Washington, D.C.: American Psychiatric Press; 2001.
22. Small JG, Milstein V. Lithium interactions: lithium and electroconvulsive therapy. J Clin Psychopharmacol. 1990;10:346-350.
23. Sackeim HA. Electroconvulsive therapy in late-life depression. In: Roose SP, Sackeim HA, eds. Late-Life Depression. New York, NY: Oxford University Press; 2004:241-278.
24. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. Report. Am J Geriatr Psychiatry. 2001;9:382-390.
25. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res. 1990;31:287-296.
26. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
27. Kellner CH, Fink M. The efficacy of ECT and "treatment resistance". J ECT. 2002;18:1-2.
28. Rasmussen KG, Mueller M, Rummans TA, et al. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). J Clin Psychiatry. 2009;70:232-237.
29. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology. 2009;34:522-534.
30. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507-516.
31. Rush AJ. STARD: what have we learned? Am J Psychiatry. 2007;164:201-204.
32. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
33. DeBattista C, Mueller K. Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder? J ECT. 2001;17:91-98.
34. Feske U, Mulsant BH, Pilkonis PA, et al. Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. Am J Psychiatry. 2004;161:2073-2080.
35. Thase ME. The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Psychiatr Clin North Am. 1996;19:287-309.
36. Klein D, Gittelman R, Quitkin F, et al. Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children. Baltimore, MD: Williams and Wilkins; 1980.
37. Sackeim HA, Brannan SK, John Rush A, et al. Durability of antidepressant response to vagus nerve stimulation (VNSTM). Int J Neuropsychopharmacol. 2007;10:817-826.